HT-1 drug study in china: just watching, no new treatment
NCT ID NCT06227429
First seen Jan 06, 2026 · Last updated Apr 28, 2026 · Updated 18 times
Summary
This study was designed to observe patients with hereditary tyrosinemia type 1 (HT-1) in China who are already taking nitisinone. The goal was to track side effects, deaths, liver transplants, and liver cancer. However, the study was withdrawn before enrolling anyone, so no results were collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY TYROSINEMIA, TYPE I are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Swedish Orphan Biovitrum Research Site
Beijing, China
-
Swedish Orphan Biovitrum Research Site
Chongqing, China
-
Swedish Orphan Biovitrum Research Site
Hefei, China
-
Swedish Orphan Biovitrum Research Site
Wuhan, China
Conditions
Explore the condition pages connected to this study.